Nebulised granulocyte-macrophage colony-stimulating factor (GM-CSF) in autoimmune pulmonary alveolar proteinosis: a systematic review and meta-analysis

被引:9
作者
Munsif, Maitri [1 ,2 ,3 ]
Sweeney, Duncan [2 ,3 ]
Leong, Tracy L. [2 ,3 ,4 ]
Stirling, Rob G. [1 ,5 ]
机构
[1] Alfred Hlth, Dept Resp Med, Melbourne, Australia
[2] Austin Hlth, Dept Resp & Sleep Med, Melbourne, Australia
[3] Austin Hlth, Inst Breathing & Sleep, Melbourne, Australia
[4] Univ Melbourne, Dept Med, Melbourne, Australia
[5] Monash Univ, Fac Med Nursing & Hlth Sci, Cent Clin Sch, Melbourne, Australia
关键词
WHOLE-LUNG LAVAGE; MINIMAL IMPORTANT DIFFERENCE; DIFFUSING-CAPACITY; CARBON-MONOXIDE; THERAPY; AUTOANTIBODIES; INHALATION; EFFICACY; DISTANCE; SAFETY;
D O I
10.1183/16000617.0080-2023
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: Autoimmune pulmonary alveolar proteinosis (aPAP) results from impaired macrophagemediated clearance of alveolar surfactant lipoproteins. Whole lung lavage has been the first-line treatment but recent reports suggest the efficacy of granulocyte-macrophage colony-stimulating factor (GM-CSF). We aimed to review the efficacy and safety of nebulised GM-CSF in aPAP.Methods: We conducted a systematic review and meta-analysis searching Embase, CINAHL, MEDLINE and Cochrane Collaborative databases (1946-1 April 2022). Studies included patients aged >18 years with aPAP receiving nebulised GM-CSF treatment and a comparator cohort. Exclusion criteria included secondary or congenital pulmonary alveolar proteinosis, GM-CSF allergy, active infection or other serious medical conditions. The protocol was prospectively registered with PROSPERO (CRD42021231328). Outcomes assessed were St George's Respiratory Questionnaire (SGRQ), 6-min walk test (6MWT), gas exchange (diffusing capacity of the lung for carbon monoxide (DLCO) % predicted) and arterial-alveolar oxygen gradient.Results: Six studies were identified for review and three for meta-analysis, revealing that SGRQ score (mean difference -8.09, 95% CI -11.88- -4.3, p<0.0001), functional capacity (6MWT) (mean difference 21.72 m, 95% CI -2.76-46.19 m, p=0.08), gas diffusion (DLCO % predicted) (mean difference 5.09%, 95% CI 2.05-8.13%, p=0.001) and arterial-alveolar oxygen gradient (mean difference -4.36 mmHg, 95% CI -7.19- -1.52 mmHg, p=0.003) all significantly improved in GM-CSF-treated patients with minor statistical heterogeneity (I2=0%). No serious trial-related adverse events were reported.Conclusions: Patients with aPAP treated with inhaled GM-CSF demonstrated significant improvements in symptoms, dyspnoea scores, lung function, gas exchange and radiology indices after treatment with nebulised GM-CSF of varying duration. There is an important need to review comparative effectiveness and patient choice in key clinical outcomes between the current standard of care, whole lung lavage, with the noninvasive treatment of nebulised GM-CSF in aPAP.
引用
收藏
页数:12
相关论文
共 45 条
  • [41] Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia
    Tsimberidou, AM
    Kantarjian, HM
    Cortes, J
    Thomas, DA
    Faderl, S
    Garcia-Manero, G
    Verstovsek, S
    Ferrajoli, A
    Wierda, W
    Alvarado, Y
    O'Brien, SM
    Albitar, M
    Keating, MJ
    Giles, FJ
    CANCER, 2003, 97 (07) : 1711 - 1720
  • [42] Colony-Stimulating Factors on Mobilizing CD34+ Cells and Improving Neurological Functions in Patients With Stroke: A Meta-Analysis and a Systematic Review
    Chen, Xiuqi
    Sun, Wenbo
    Zhong, Ping
    Wu, Danhong
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [43] Beyond CD34+cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day+100 hematopoietic graft function
    Alexander, Erin T.
    Towery, Jeanne A.
    Miller, Ashley N.
    Kramer, Cindy
    Hogan, Kathy R.
    Squires, Jerry E.
    Stuart, Robert K.
    Costa, Luciano J.
    TRANSFUSION, 2011, 51 (09) : 1995 - 2000
  • [44] Combination treatment with anti-HER2 therapeutic antibody RC48, PD-1 inhibitor, radiotherapy, and granulocyte macrophage-colony stimulating factor (GM-CSF) in patient with metastatic gastric cancer: a case report
    Liu, Zhuixing
    Wang, Fang
    Zhang, Yingqi
    Lu, Jun
    Yang, Yang
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [45] Prophylactic use of granulocyte colony-stimulating factor after induction chemotherapy in patients with newly diagnosed acute myeloid leukemia may increase the complete remission rate: a meta-analysis of five randomised controlled trials
    Wang, Jing
    Zhan, Ping
    Ouyang, Jian
    Chen, Bing
    Zhou, Rongfu
    LEUKEMIA & LYMPHOMA, 2009, 50 (03) : 457 - 459